Latest Growth Strategy News

CONNEQT Health has landed a significant Phase 2b clinical trial contract in the US, advancing its footprint in cardiovascular disease research with proprietary vascular assessment technology.

Arovella Therapeutics has secured encouraging feedback from the US FDA on reagent testing for its CAR-iNKT cell therapy, setting the stage for an IND filing this quarter and clinical trials in early 2026.

BetMakers Technology Group has reported a remarkable 361% growth in adjusted EBITDA for Q1 FY26, driven by strong revenue gains and operational efficiencies, while advancing its strategic expansion into the Las Vegas racing market.

Fluence Corporation has landed a significant $12 million contract to supply an ultra-pure water treatment system for a new power plant in Saudi Arabia, marking a strategic expansion in the Middle East.

Credit Corp Group Limited reported strong earnings growth in 2025, driven by its diversified financial services portfolio and strategic expansion into the UK market, alongside significant advances in AI technology.

Ramelius Resources has released a Definitive Feasibility Study for its Rebecca-Roe Gold Project, confirming strong economics with a post-tax NPV of A$692 million and average annual production of 130,000 ounces over nine years.

Resolute Mining’s Q3 2025 report reveals steady gold production tempered by seasonal and supply challenges, while major projects in Mali, Senegal, and Côte d’Ivoire progress on schedule with expanding resources.

Develop Global reports strong September quarter progress with Woodlawn mine ramping up on schedule and Sulphur Springs DFS doubling projected cashflow to A$1.5 billion. A major mining services contract extension further bolsters the company’s growth outlook.

Kingfisher Mining secures shareholder approval for NSW tenement acquisition and accelerates exploration at Copper Blow and Mick Well REE projects, backed by a solid $2.35 million cash position.

Coast Entertainment’s Dreamworld development application has been called-in by the Queensland Minister, while the company reports robust FY26 trading growth and nears completion of its new King Claw ride.

MCS Services Limited reported a $644k cash outflow from operations in Q1 2025 while lodging multiple traffic management tenders and exploring growth strategies. The company continues to consider selling its Traffic Business subsidiary, Highways Traffic Pty Ltd.

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.